89985-86-4

Basic information

• Product Name: (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate
• Synonyms: (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate;tert-Butyl [(1R)-1-(hydroxymethyl)prop-2-en-1-yl]carbamate;89985-86-4
• CAS NO: 89985-86-4
• Molecular Formula: C₉H₁₇NO₃
• Molecular Weight: 187
• Mol File: 89985-86-4.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 302.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.026±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 11.60±0.46(Predicted)
• CAS DataBase Reference: (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate(89985-86-4)
• EPA Substance Registry System: (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate(89985-86-4)

Safety Data

• Hazardous Substances Data: 89985-86-4(Hazardous Substances Data)

Usage

General Description

(R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate is a chemical compound with the molecular formula C9H17NO3. It is a carbaMate derivative, containing a tert-butyl group and a hydroxybut-3-en-2-yl group. (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate has potential applications in the pharmaceutical industry, particularly in the development of new drugs or therapeutic agents. Its structure and properties make it a valuable candidate for further research and exploration in the fields of drug discovery and development. Additionally, its unique chemical composition and reactivity may offer benefits in various chemical and industrial processes. Further studies and investigations are necessary to fully understand the potential uses and applications of (R)-tert-butyl 1-hydroxybut-3-en-2-ylcarbaMate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 174810-06-1 (+)-2-[(1R)-(hydroxymethyl)prop-2-enyl]-1H-isoindole-1,3-(2H)-dione 
• 313995-40-3 (2R)-1-Hydroxybut-3-en-2-amine hydrochloride 
• 913344-40-8 tert-butyl N-formyl carbamate 
• 318469-73-7 (2E)-4-hydroxybut-2-en-1-yl methyl carbonate 
• 930-22-3 epoxybutene 
• 88000-67-3 tert-butyl benzoylimidocarboxylate 
• 33900-24-2 (R)-2-tert-Butoxycarbonylamino-4-methylsulfanyl-butyric acid methyl ester 
• 2488-15-5 N-t-butoxycarbonyl-D-methionine 
• 91177-57-0 tert-butyl (1R)-1-(hydroxymethyl)-3-(methylsulfanyl)propylcarbamate 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 
• 95715-87-0 (R)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyloxazolidine 
• 2766-43-0 N-tert-butyloxycarbonyl-L-serine methyl ester 
• 89985-60-4 (R)-2-aminobut-3-en-1-ol 

Downstream Products

• 156714-71-5 (3S,5S)-2-benzyl-5-((1S)-1-tert-butoxycarbonylamino-2-hydroxyethyl)-3-tridecylisoxazolidine 
• 156714-72-6 (3S,5R)-2-benzyl-5-((1S)-1-tert-butoxycarbonylamino-2-hydroxyethyl)-3-tridecylisoxazolidine 
• 156714-70-4 (3R,5R)-2-benzyl-5-((1S)-1-tert-butoxycarbonylamino-2-hydroxyethyl)-3-tridecylisoxazolidine 
• 91103-36-5 N-tert.-butyloxycarbonyl-L-serinal 
• 92085-86-4 (+)-tert-butyl {(1R)-1-[(benzyloxy)methyl]prop-2-en-1-yl}carbamate 
• 89985-60-4 (R)-2-aminobut-3-en-1-ol 
• 917365-48-1 C₂₆H₃₁BrN₂O₆S 
• 917365-50-5 C₂₆H₃₁BrN₂O₆S 
• 917365-69-6 C₃₆H₃₉BrN₄O₁₀S₂ 
• 917365-56-1 C₂₆H₂₉BrN₂O₆S 
• 91103-43-4 (S)-2-{(R)-2-[tert-Butoxycarbonyl-((R)-2-tert-butoxycarbonylamino-3-hydroxy-propyl)-amino]-3-hydroxy-propylamino}-succinic acid dibenzyl ester 
• 91103-44-5 (S)-2-(tert-Butoxycarbonyl-{(R)-2-[tert-butoxycarbonyl-((R)-2-tert-butoxycarbonylamino-3-hydroxy-propyl)-amino]-3-hydroxy-propyl}-amino)-succinic acid dibenzyl ester 
• 271260-96-9 (R)-3-(tert-butoxycarbonyl)-4-[2-(2,4,6-trimethylphenyl)ethyl]-2,2-dimethyloxazolidine 

Relevant articles and documents

Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors

An alternative medicinal chemistry approach was conducted on Bruton's tyrosine kinase (BTK) inhibitor 1 (ibrutinib) by merging the pyrazolo[3,4-d]pyrimidine component into a tricyclic skeleton. Two types of compounds were prepared, and their biochemical activities on BTK as well as stereochemistry effects were determined. Structural optimization focusing on the reactive binding group to BTK Cys481 and on the metabolic site guided by metabolic study were conducted. 7S was identified as the most potent showing an IC50 value of 0.4 nM against BTK and 16 nM against BTK-dependent TMD8 cells. Compared to 1, 7S was slightly more selective with strong inhibition on the B-cell receptor signaling pathway. In a TMD8 cell-derived animal xenograft model, 7S showed a relative tumor volume of 5.3 at 15 mg/kg QD dosage that was more efficacious than 1 (RTV 6.6) at a higher dose of 25 mg/kg QD. All these results suggest 7S as a new BTK inhibitor worthy of further profiling.

Modular Construction of Protected 1,2/1,3-Diols, -Amino Alcohols, and -Diamines via Catalytic Asymmetric Dehydrative Allylation: An Application to Synthesis of Sphingosine

A new enantioselective catalysis has been developed for the one-step construction of methylene-bridged chiral modules of 1,2- and 1,3-OH and/or NH function(s) from δ- or λ-OH/NHBoc-substituted allylic alcohols and H2C=O / H2C=NBoc . A protonic nucleophile, either in situ-generated CH2OH or CH2NHBoc, is intramolecularly allylated to furnish eight possible 1,2- or 1,3-O,O, -O,N, -N,O, and -N,N chiral modules equipped with an ethenyl group in high yields and enantioselectivities. The utility of this method has been demonstrated in the five-step synthesis of sphingosine.

Progress toward the total synthesis of lucentamycin A: Total synthesis and biological evaluation of 8-epi-lucentamycin A

(Chemical Equation Presented) Synthetic efforts toward the cytotoxic peptides lucentamycins A-D are described that resulted in the total synthesis and biological evaluation of 8-epi-lucentamycin A in 15 steps with 2.2% overall yield. The key epinonproteog